Berkeley Lights Launches Assay Series for Early Cell-Line Development Yield and Product Quality
The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
Berkeley Lights, a US-based digital cell biology company, announced on April 5, 2021 that it has launched Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
According to a company press release, the first series supports direct detection of product aggregates for a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process, allowing for customers to rapidly choose clonal cell lines with promising manufacturability profiles.
“We’re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resources spent on preventing product failures downstream and ensure a more efficient process,” said John Proctor, PhD, senior vice-president of Antibody Therapeutics at Berkeley Lights, in the press release.
Source: Berkeley Lights
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
